- At ProCyte Corporation revenues declined from $1.3 million in the 1994 third quarter to $684,382. In the first nine months of 1995 revenues were up 6.5% to $3.4 million. The net loss for the three-month period was $1.4 million or $0.11, a reduction on the previous year. In the nine-month period the loss was $4.2 million, compared with $9.2 million. Research, development and regulatory expenses decreased around 73% from the year-ago quarter, primarily due to completion of the Phase III study of Iamin gel.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze